Pharmaceutical Technology
JULY 29, 2022
Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. In preparation for this, drug manufacturing will begin later this year and will be outsourced to external contract manufacturing organisations (CMOs).
pharmaphorum
JANUARY 6, 2021
million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. The nomination of a first candidate in the collaboration that will advance into development triggers a $2.5
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 27, 2020
The company opted to test merimepodib in the combination trial first as that had the greatest potential to make a difference to patients, but the safety issue means that it has decided to halt development of the drug altogether. Just a few weeks later, and the study comparing Veklury plus merimepodib to Veklury plus placebo has failed.
Roots Analysis
FEBRUARY 21, 2022
Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine. As per our analysis, majority of the kits use purified RNA / DNA as the input sample. Nanoparticles Contract Manufacturing.
pharmaphorum
JANUARY 7, 2021
It gave CureVac €75 million in funding to develop CVnCoV last July, adding to around €100 million provided by the German government in 2020. At last count, there are more than 60 coronavirus vaccines at in clinical development around the world, with another 170 in preclinical testing, according to the World Health Organization (WHO).
The Pharma Data
NOVEMBER 19, 2021
.” PF-07321332 is designed to block the exertion of the SARS-CoV-2-3CL protease, an enzyme that the coronavirus needs to replicate, at a stage known as proteolysis-which occurs before viral RNA replication. Each case was randomized (11) to admit PAXLOVID or placebo orally every 12 hours for five days.
The Pharma Data
MARCH 22, 2022
Pfizer continues to invest to support the manufacturing and distribution of PAXLOVID, including exploring potential contract manufacturing options. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication.
Expert insights. Personalized for you.
245 
Let's personalize your content